🇺🇸 FDA
Patent

US 12404337

Compositions, doses, and methods for treatment of thyroid eye disease

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 12404337 (Compositions, doses, and methods for treatment of thyroid eye disease) held by Viridian Therapeutics, Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Viridian Therapeutics, Inc.
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/55